Category: Alzheimer’s Disease (Page 7)

May 1, 2013

NIH ADRD Conference

At this conference, leading neuroscientists, physicians, and public and private stakeholders will discuss key challenges and special opportunities in research on Alzheimer’s disease-related dementias.
February 7, 2013

Statement on FDA Draft Guidance for Alzheimer’s Drug Development

Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) coalition released a statement in response to guidance from the U.S. Food and Drug Administration (FDA) on the development of drugs for Alzheimer’s Disease.
December 18, 2012

Recommendations for Advancing Alzheimer’s Interventions

This week the Alliance for Aging Research and the U.S. Administration on Aging (AoA) released a new white paper titled Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer's disease and their caregivers at home and in their communities.
November 29, 2012

FDA/AD Allies Meeting on Combination Therapy Development

To address critical issues in the development of new Alzheimer’s disease treatments, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) coalition and the Critical Path Institute will co-host the fifth-annual FDA/AD Allies Meeting. This annual meeting sponsored by ACT-AD brings together leaders in Alzheimer’s drug development from the patient advocacy community, federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of Alzheimer’s drugs and therapies.
June 1, 2012

Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer’s disease and their caregivers at home and in the community

This white paper presents the findings and recommendations from a review of the state of the art non-pharmacological treatments and…
June 1, 2012

Translating Innovation to Impact: Pre-reads

On June 28, 2012 the Alliance for Aging Research and its project partner the U.S. Administration on Aging (AoA), convened Translating Innovation to Impact, a one-day working meeting to review the state of research into evidence-based interventions to help people with Alzheimer’s remain healthy and independent in the community while reducing the stress on their caregivers. This document provides the agenda and pre-reads for that important meeting.
February 9, 2012

Big Boost for Alzheimer’s

This week’s press event announcing an immediate $50 million infusion of NIH funding to Alzheimer’s research—along with commitments to include an additional $80 million in research dollars and $26 million in services and supports in the President’s FY 2013 budget—was monumental on a number of fronts.
February 1, 2012

Ready for Prime Time

Thought Experiment: Biomarkers of Alzheimer’s disease are ready for widespread use in clinical trials.
January 9, 2012

Responding to the Aging of the Population

A group of aging and Alzheimer’s advocates will be meeting this week with the senior leadership of the National Institutes of Health (NIH) to call for an increase in funding for the National Institute on Aging (NIA). In advance of this meeting, the group has orchestrated a sign-on letter to demonstrate widespread support for $1.4 billion, an increase of $300 million, in the FY 2013 NIH Budget to support the NIA. A similar letter was generated last year and garnered more than 400 signatures.
January 6, 2012

Are we there yet?

Many of you may still have this phrase ringing in your ears if you traveled with children for any length of time this past holiday season. Representatives from the ACT-AD Coalition, chaired by the Alliance for Aging Research, heard these same words almost two years ago, not uttered from the mouths of babes, but rather by prominent officials at the Food and Drug Administration (FDA) in a conversation regarding evidence to support the use of biomarkers for Alzheimer’s disease in clinical trials for “disease-modifying” therapies.